Post-SSRI Sexual Dysfunction (PSSD): Incidence and Prevalence
The risk of developing persistent sexual dysfunction after stopping SSRIs (PSSD) is estimated at approximately 0.46% (1 in 216 patients treated), with a population prevalence of 4.3 per 100,000. 1
Key Epidemiological Data
The most robust estimate comes from a 19-year retrospective cohort study of 12,302 males aged 21-49 without confounding medical conditions, which found:
- Incidence rate: 0.46% (1 in 216 patients treated with serotonergic antidepressants) 1
- Population prevalence: 4.3 per 100,000 1
- Crude odds ratio for erectile dysfunction: 3.6 (95% CI 2.8-4.8, p < 0.000001) 1
- Adjusted odds ratio: 3.2 after controlling for age, socioeconomic status, BMI, depression, and anxiety (95% CI 2.3-4.4, p < 0.000001) 1
Significant Barriers to Accurate Quantification
The true incidence is likely underestimated due to multiple systematic obstacles 2:
- Patient embarrassment prevents reporting of sexual concerns to healthcare providers 2
- Healthcare professional dismissiveness when patients do report persistent symptoms 2
- Patient unawareness that sexual difficulties are medication-related, particularly when symptoms emerge after discontinuation 2
- Inability to discontinue antidepressants due to withdrawal symptoms in many patients, preventing identification of persistent dysfunction 2
- Lack of standardized diagnostic criteria until recently 2
Clinical Characteristics from Available Data
Analysis of 86 Dutch pharmacovigilance reports revealed 3:
- Duration of persistence: Cases ranged from 2 months to 23 years after SSRI discontinuation 3
- Most common symptoms: Decreased/loss of libido (n=53), erectile dysfunction (n=23), anorgasmia (n=5) 3
- SSRI types implicated: 92% had history of SSRI use, 8% SNRI or atypical antidepressants 4
Symptom Trajectory and Recovery
Survey data from 239 individuals with PSSD showed 4:
- 45% experienced symptom improvement after discontinuation 4
- 37% had symptoms that worsened or remained unchanged after discontinuation 4
- Quality of life impact: 59% rated the effect as "extremely negative," 23% as "very negative" 4
Critical Clinical Caveat
Only 12% of patients reported being counseled about potential sexual dysfunction before starting antidepressants 4. This represents a significant informed consent gap, particularly given that sexual dysfunction during active SSRI treatment is well-documented in guidelines 5, 6, 7.
Comparison to Acute SSRI-Related Sexual Dysfunction
While PSSD affects approximately 0.46% of treated patients 1, sexual dysfunction during active SSRI treatment is far more common:
- Paroxetine shows higher rates of sexual dysfunction than fluoxetine, fluvoxamine, nefazodone, or sertraline during treatment 6
- Bupropion demonstrates significantly lower rates of sexual adverse events (8%) compared to fluoxetine or sertraline during active treatment 6
- Sexual dysfunction (erectile dysfunction, delayed ejaculation, anorgasmia) can occur with SSRIs in adolescents during treatment 5
Recognition and Documentation
A MedDRA code for PSSD has been introduced but has not yet been adopted by regulatory agencies 2. The condition now has published diagnostic criteria 2, which should facilitate future epidemiological research and clinical recognition.